# GoodRx Holdings, Inc.: financial statements, quarterly

GDRX · Nasdaq · CIK 1809519 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gdrx.md) · [Financials](/companies/gdrx/financials.md) · [Filings](/companies/gdrx/filings.md) · [Insiders](/companies/gdrx/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gdrx/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [180](/filings/0001809519-24-000196.md) | [197 d](/filings/0001809519-26-000031.md) | [198](/filings/0001809519-25-000075.md) | [201](/filings/0001809519-25-000117.md) | [195](/filings/0001809519-25-000143.md) | [199 d](/filings/0001809519-26-000031.md) | [203](/filings/0001809519-26-000111.md) | [203](/filings/0001809519-26-000152.md) | [196](/filings/0001809519-25-000143.md) | [195 d](/filings/0001809519-26-000031.md) | [194](/filings/0001809519-26-000111.md) | [200](/filings/0001809519-26-000152.md) |
| Research and development | $m | [39.6](/filings/0001809519-24-000196.md) | [32.0 d](/filings/0001809519-26-000031.md) | [31.0](/filings/0001809519-25-000075.md) | [30.9](/filings/0001809519-25-000117.md) | [30.1](/filings/0001809519-25-000143.md) | [31.7 d](/filings/0001809519-26-000031.md) | [31.1](/filings/0001809519-26-000111.md) | [29.9](/filings/0001809519-26-000152.md) | [31.0](/filings/0001809519-25-000143.md) | [28.9 d](/filings/0001809519-26-000031.md) | [30.2](/filings/0001809519-26-000111.md) | [26.7](/filings/0001809519-26-000152.md) |
| Operating income | $m | [(38.3)](/filings/0001809519-24-000196.md) | [(18.3) d](/filings/0001809519-26-000031.md) | [7.4](/filings/0001809519-25-000075.md) | [19.9](/filings/0001809519-25-000117.md) | [20.4](/filings/0001809519-25-000143.md) | [18.2 d](/filings/0001809519-26-000031.md) | [23.4](/filings/0001809519-26-000111.md) | [26.8](/filings/0001809519-26-000152.md) | [14.6](/filings/0001809519-25-000143.md) | [22.7 d](/filings/0001809519-26-000031.md) | [14.0](/filings/0001809519-26-000111.md) | [23.6](/filings/0001809519-26-000152.md) |
| Interest expense | $m | [14.7](/filings/0001809519-24-000196.md) | [14.8 d](/filings/0001809519-26-000031.md) | [14.6](/filings/0001809519-25-000075.md) | [14.6](/filings/0001809519-25-000117.md) | [12.4](/filings/0001809519-25-000143.md) | [11.4 d](/filings/0001809519-26-000031.md) | [10.6](/filings/0001809519-26-000111.md) | [10.7](/filings/0001809519-26-000152.md) | [10.8](/filings/0001809519-25-000143.md) | [10.4 d](/filings/0001809519-26-000031.md) | [9.8](/filings/0001809519-26-000111.md) | [9.8](/filings/0001809519-26-000152.md) |
| Income tax | $m | [(8.1)](/filings/0001809519-24-000196.md) | [1.2 d](/filings/0001809519-26-000031.md) | [1.3](/filings/0001809519-25-000075.md) | [5.0](/filings/0001809519-25-000117.md) | [4.1](/filings/0001809519-25-000143.md) | [4.7 d](/filings/0001809519-26-000031.md) | [5.6](/filings/0001809519-26-000111.md) | [6.7](/filings/0001809519-26-000152.md) | [5.0](/filings/0001809519-25-000143.md) | [8.8 d](/filings/0001809519-26-000031.md) | [4.5](/filings/0001809519-26-000111.md) | [6.9](/filings/0001809519-26-000152.md) |
| Net income | $m | [(38.5)](/filings/0001809519-24-000196.md) | [(25.9) d](/filings/0001809519-26-000031.md) | [(1.0)](/filings/0001809519-25-000143.md) | [6.7](/filings/0001809519-25-000143.md) | [4.0](/filings/0001809519-25-000143.md) | [6.7 d](/filings/0001809519-26-000031.md) | [11.1](/filings/0001809519-26-000152.md) | [12.8](/filings/0001809519-26-000152.md) | [1.1](/filings/0001809519-25-000143.md) | [5.4 d](/filings/0001809519-26-000031.md) | [1.2](/filings/0001809519-26-000152.md) | [8.5](/filings/0001809519-26-000152.md) |
| Diluted EPS | $ per share | [(0.09)](/filings/0001809519-24-000196.md) | not reported | [0.00](/filings/0001809519-25-000075.md) | [0.02](/filings/0001809519-25-000117.md) | [0.01](/filings/0001809519-25-000143.md) | not reported | [0.03](/filings/0001809519-26-000111.md) | [0.04](/filings/0001809519-26-000152.md) | [0.00](/filings/0001809519-25-000143.md) | not reported | [0.00](/filings/0001809519-26-000111.md) | [0.02](/filings/0001809519-26-000152.md) |
| Basic EPS | $ per share | [(0.09)](/filings/0001809519-24-000196.md) | not reported | [0.00](/filings/0001809519-25-000075.md) | [0.02](/filings/0001809519-25-000117.md) | [0.01](/filings/0001809519-25-000143.md) | not reported | [0.03](/filings/0001809519-26-000111.md) | [0.04](/filings/0001809519-26-000152.md) | [0.00](/filings/0001809519-25-000143.md) | not reported | [0.00](/filings/0001809519-26-000111.md) | [0.03](/filings/0001809519-26-000152.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [795](/filings/0001809519-23-000036.md) | [672](/filings/0001809519-25-000040.md) | [533](/filings/0001809519-24-000083.md) | [525](/filings/0001809519-24-000164.md) | [424](/filings/0001809519-24-000196.md) | [448](/filings/0001809519-26-000031.md) | [301](/filings/0001809519-25-000075.md) | [281](/filings/0001809519-25-000117.md) | [274](/filings/0001809519-25-000143.md) | [262](/filings/0001809519-26-000152.md) | [236](/filings/0001809519-26-000111.md) | [296](/filings/0001809519-26-000152.md) |
| Current assets | $m | [969](/filings/0001809519-23-000036.md) | [873](/filings/0001809519-25-000040.md) | [733](/filings/0001809519-24-000083.md) | [751](/filings/0001809519-24-000164.md) | [627](/filings/0001809519-24-000196.md) | [659](/filings/0001809519-26-000031.md) | [540](/filings/0001809519-25-000075.md) | [551](/filings/0001809519-25-000117.md) | [566](/filings/0001809519-25-000143.md) | [643](/filings/0001809519-26-000152.md) | [1,266](/filings/0001809519-26-000111.md) | [1,599](/filings/0001809519-26-000152.md) |
| Total assets | $m | [1,708](/filings/0001809519-23-000036.md) | [1,589](/filings/0001809519-25-000040.md) | [1,454](/filings/0001809519-24-000083.md) | [1,475](/filings/0001809519-24-000164.md) | [1,355](/filings/0001809519-24-000196.md) | [1,388](/filings/0001809519-26-000031.md) | [1,295](/filings/0001809519-25-000075.md) | [1,319](/filings/0001809519-25-000117.md) | [1,326](/filings/0001809519-25-000143.md) | [1,404](/filings/0001809519-26-000152.md) | [2,021](/filings/0001809519-26-000111.md) | [2,343](/filings/0001809519-26-000152.md) |
| Current liabilities | $m | [118](/filings/0001809519-23-000036.md) | [123](/filings/0001809519-25-000040.md) | [117](/filings/0001809519-24-000083.md) | [102](/filings/0001809519-24-000164.md) | [114](/filings/0001809519-24-000196.md) | [124](/filings/0001809519-26-000031.md) | [103](/filings/0001809519-25-000075.md) | [131](/filings/0001809519-25-000117.md) | [182](/filings/0001809519-25-000143.md) | [246](/filings/0001809519-26-000152.md) | [859](/filings/0001809519-26-000111.md) | [1,158](/filings/0001809519-26-000152.md) |
| Total liabilities | $m | [827](/filings/0001809519-23-000036.md) | [827](/filings/0001809519-25-000040.md) | [823](/filings/0001809519-24-000083.md) | [806](/filings/0001809519-24-000164.md) | [658](/filings/0001809519-24-000196.md) | [663](/filings/0001809519-26-000031.md) | [641](/filings/0001809519-25-000075.md) | [676](/filings/0001809519-25-000117.md) | [725](/filings/0001809519-25-000143.md) | [788](/filings/0001809519-26-000152.md) | [1,399](/filings/0001809519-26-000111.md) | [1,695](/filings/0001809519-26-000152.md) |
| Long-term debt | $m | [649](/filings/0001809519-23-000036.md) | [648](/filings/0001809519-25-000040.md) | [647](/filings/0001809519-24-000083.md) | [646](/filings/0001809519-24-000164.md) | [488](/filings/0001809519-24-000196.md) | [487](/filings/0001809519-26-000031.md) | [486](/filings/0001809519-25-000075.md) | [485](/filings/0001809519-25-000117.md) | [484](/filings/0001809519-25-000143.md) | [483](/filings/0001809519-26-000152.md) | [482](/filings/0001809519-26-000111.md) | [482](/filings/0001809519-26-000152.md) |
| Current portion of debt | $m | [7.0](/filings/0001809519-23-000036.md) | [8.8](/filings/0001809519-25-000040.md) | [7.0](/filings/0001809519-24-000083.md) | [7.0](/filings/0001809519-24-000164.md) | [3.8](/filings/0001809519-24-000196.md) | [5.0](/filings/0001809519-26-000031.md) | [5.0](/filings/0001809519-25-000075.md) | [5.0](/filings/0001809519-25-000117.md) | [5.0](/filings/0001809519-25-000143.md) | [5.0](/filings/0001809519-26-000152.md) | [5.0](/filings/0001809519-26-000111.md) | [5.0](/filings/0001809519-26-000152.md) |
| Shareholders' equity | $m | [881](/filings/0001809519-24-000196.md) | [762](/filings/0001809519-26-000031.md) | [631](/filings/0001809519-25-000143.md) | [669](/filings/0001809519-25-000143.md) | [696](/filings/0001809519-25-000143.md) | [725](/filings/0001809519-26-000152.md) | [654](/filings/0001809519-26-000152.md) | [643](/filings/0001809519-26-000152.md) | [601](/filings/0001809519-25-000143.md) | [616](/filings/0001809519-26-000152.md) | [622](/filings/0001809519-26-000152.md) | [648](/filings/0001809519-26-000152.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [60.3 d](/filings/0001809519-24-000196.md) | [15.9 d](/filings/0001809519-26-000031.md) | [42.6](/filings/0001809519-25-000075.md) | [9.7 d](/filings/0001809519-25-000117.md) | [86.9 d](/filings/0001809519-25-000143.md) | [44.7 d](/filings/0001809519-26-000031.md) | [9.4](/filings/0001809519-26-000111.md) | [49.6 d](/filings/0001809519-26-000152.md) | [76.0 d](/filings/0001809519-25-000143.md) | [32.9 d](/filings/0001809519-26-000031.md) | [11.8](/filings/0001809519-26-000111.md) | [80.8 d](/filings/0001809519-26-000152.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001809519-24-000196.md) | [0.4 d](/filings/0001809519-26-000031.md) | [0.4](/filings/0001809519-25-000075.md) | [0.3 d](/filings/0001809519-25-000117.md) | [0.4 d](/filings/0001809519-25-000143.md) | [0.2 d](/filings/0001809519-26-000031.md) | [0.1](/filings/0001809519-26-000111.md) | [0.4 d](/filings/0001809519-26-000152.md) | [1.7 d](/filings/0001809519-25-000143.md) | [1.2 d](/filings/0001809519-26-000031.md) | [1.1](/filings/0001809519-26-000111.md) | [0.4 d](/filings/0001809519-26-000152.md) |
| Share repurchases | $m | [7.7 d](/filings/0001809519-24-000196.md) | [77.8 d](/filings/0001809519-26-000031.md) | [153](/filings/0001809519-25-000075.md) | [0.0 d](/filings/0001809519-25-000117.md) | [5.4 d](/filings/0001809519-25-000143.md) | [0.2 d](/filings/0001809519-26-000031.md) | [99.9](/filings/0001809519-26-000111.md) | [46.0 d](/filings/0001809519-26-000152.md) | [61.1 d](/filings/0001809519-25-000143.md) | [9.4 d](/filings/0001809519-26-000031.md) | [12.6](/filings/0001809519-26-000111.md) | [2.0 d](/filings/0001809519-26-000152.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [413](/filings/0001809519-23-000036.md) | [412](/filings/0001809519-24-000083.md) | [414](/filings/0001809519-24-000164.md) | [413](/filings/0001809519-24-000196.md) | [390](/filings/0001809519-25-000075.md) | [385](/filings/0001809519-25-000117.md) | [389](/filings/0001809519-25-000143.md) | [380](/filings/0001809519-26-000111.md) | [357](/filings/0001809519-26-000152.md) | [348](/filings/0001809519-25-000143.md) | [341](/filings/0001809519-26-000111.md) | [348](/filings/0001809519-26-000152.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.